Scientific papers

High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'

CHRISTIAN VINCENT,¹ GUY SERRE,¹ FREDERIC LAPEYRE,²
BERNARD FOURNIÉ,² CHRISTIANE AYROLLES,² ANTOINE FOURNIÉ,²
AND JEAN-PIERRE SOLEILHAVOUP¹

From the ¹Département de Biologie Cellulaire et d'Histologie and the ²Clinique de Rhumatologie, Hôpital Purpan, Toulouse, France

SUMMARY Serum antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies', have been largely demonstrated in rheumatoid arthritis (RA). IgM and IgG antibodies to this epithelium were studied by semiquantitative immunofluorescence in 529 patients with perfectly characterised rheumatic diseases, including 178 with classical or definite RA. Histological analysis of IgG antibodies showed that only antibodies which produce a linear laminated pattern restricted to the stratum corneum (IgG antikeratin antibodies) are highly specific for RA; all the other labelling patterns are not disease specific. By a semiquantitative evaluation of the stratum corneum fluorescence intensity it was shown that the diagnostic value of IgG antikeratin antibodies closely depends on their titre and it was established in objective conditions that the sensitivity is 43.26% when the specificity reaches 99.14%. A high titre of IgG antikeratin antibodies was actually pathognomonic for RA. Both the histological and semiquantitative analyses showed that IgM antibodies to rat oesophagus epithelium, though frequently detected, are of no diagnostic value, either for RA or for any other rheumatic disease that was studied. From a review of all the international reports on IgG antikeratin antibodies it was found that, to date, 4080 patients, including 1694 with RA, have been assayed for antikeratin antibodies by 11 different research groups. Analysis of all the results obtained under comparable technical conditions showed that IgG antikeratin antibodies constitute the most specific serological criterion for the diagnosis of RA. Furthermore, it was found that their incidence does not depend on disease duration: they are present in one third of rheumatoid factor negative patients with RA, and they seem to be related to disease severity or activity, or both. Their detection in the diagnosis of rheumatic diseases should become systematic.

Rheumatoid arthritis (RA), like the other non-organ-specific autoimmune diseases, shows a wide variety of circulating autoantibodies. Among them, rheumatoid factor (RF) is considered as the most characteristic of the disease, but antinuclear autoantibodies and autoantibodies to various tissue antigens, such as perinuclear granules,¹⁻³ collagen,⁴

smooth muscle,⁵ and intermediate filaments,^{6,7} have also been described in RA.

Since the report by Young *et al* in 1979⁸ numerous authors^{2,3,9-17} have described, by indirect immunofluorescence in rheumatoid sera, antibodies able to label the stratum corneum of rat oesophagus epithelium. These anti-stratum corneum antibodies, generally called 'antikeratin antibodies',* have been found to be a more specific marker than the usual serological indexes of the disease, and their detection has been proposed as a diagnostic test for RA. In all these studies, however, the detection thresholds for antikeratin antibodies have been arbitrarily chosen and this has introduced some

Accepted for publication 12 January 1989.

Correspondence to Dr Christian Vincent, Département de Biologie Cellulaire et d'Histologie, CHU Purpan, Place du Dr Baylac, 31059 Toulouse Cedex, France.

*Authors' note: Research indicates that the so-called 'antikeratin antibodies' are not directly related to keratins, but for clarity the inverted commas have been omitted throughout the rest of the text.

variation in the results of different authors in the evaluation of the diagnostic sensitivity and specificity of the test.

We studied IgG and IgM antibodies to rat oesophagus epithelium, including antikeratin antibodies, in a large number of serum samples from patients with well characterised rheumatic diseases. Like previous authors we used an indirect immunofluorescence assay, but to determine objectively the diagnostic sensitivity and specificity of antikeratin antibodies we used an original semiquantitative method to study their labelling patterns in detail with regard to the other antiepithelial antibodies. This method permitted accurate grading of the fluorescence intensity without previous choice of a positivity threshold and therefore determination of a precise antikeratin antibody titre-like value. In addition, we investigated relations between antikeratin antibodies and several clinical and serological indexes of the disease. Lastly, we analysed previous international reports and determined the usefulness of antikeratin antibodies in the diagnosis of RA, and their relations with other features of the disease for all the results of tested sera published since 1979.

Patients and methods

PATIENTS

From among 3396 serum samples from 1749 patients with rheumatic diseases assayed during the past two years, we selected and studied 528 samples obtained from 528 patients with perfectly characterised diseases according to clinical, radiographic, and biological criteria (Table 1). The patients could be

divided into seven groups: group I consisted of those with classical or definite RA according to the 'old' criteria of the American Rheumatism Association^{18 19}; groups II to V were composed of patients with various inflammatory rheumatic diseases, including systemic lupus erythematosus, miscellaneous connective tissue diseases, psoriatic arthritis, and ankylosing spondylitis, respectively; the two other groups comprised patients with non-inflammatory rheumatic diseases: Paget's disease (group VI), arthrosis, compressive neuralgia, and algodystrophia (group VII).

SEMIQUANTITATIVE INDIRECT IMMUNOFLUORESCENCE

A semiquantitative indirect immunofluorescence technique, derived from semiquantitative methods largely used in histochemical studies²⁰ and previously used to investigate autoantibodies to epidermis in normal human sera,²¹ was adapted with minor changes to rat oesophagus.

The middle third^{9 11} of Wistar rat oesophagus obtained from Pel-Freez (Rogers, Arkansas) was frozen at -30°C and stored at -80°C until assay. Cryostat sections (4 µm thick) were fixed by air drying in an airtight box containing silica gel desiccant for one hour at 37°C then overnight at 4°C, without additional chemical fixation. After rehydration in pH 7.4 phosphate buffered saline (PBS) human serum samples diluted 1:10 in PBS were incubated on slides for 30 minutes at 37°C in a moist chamber. The slides were rinsed twice for five minutes in PBS and then incubated for 15 minutes at 37°C with fluorescein isothiocyanate labelled goat F(ab)₂ fragments to human IgM (µ specific) obtained from Tago (Burlingame, California) or with fluorescein isothiocyanate labelled goat F(ab) fragments to human IgG (γ specific) purchased from Biosys (Compiègne, France), diluted 1:50 in PBS. The slides were rinsed twice in PBS and mounted with Fluoprep medium (Bio-Mérieux, Lyon, France). Observations were performed on an Olympus-BH2 microscope with ultraviolet epillumination, and photographs were taken with an Olympus-OM4 camera (Tokyo, Japan).

The fluorescence intensity of each histological compartment of the cornified stratified squamous epithelium of the rat oesophagus (Fig. 1A)—that is, stratum corneum, stratum spinosum, and stratum basale, was separately estimated by two readers, who did not know the clinical context. Results were estimated on a semiquantitative scale from 0 to 4 and the results of the two readers were summed (final range 0-8). On such a scale the accuracy of the human eye reading has been found to be better than 0.50 (data not shown). Therefore a 0.25 step was

Table 1 Details of patients

Diagnosis	Number	Age median (range) of men	No(%)
Rheumatoid arthritis*	178	60 (15-86)	32 (18)
Systemic lupus erythematosus	28	48 (21-76)	5 (18)
Miscellaneous connective tissue diseases†	23	59 (25-79)	4 (17)
Psoriatic arthritis	40	53 (26-75)	27 (67.5)
Ankylosing spondylitis	44	43 (18-79)	30 (68)
Paget's disease	69	70 (37-86)	40 (58)
Miscellaneous non-inflammatory rheumatic diseases‡	146	56 (15-83)	69 (47)
Total	528	58 (15-86)	207 (39)

*Classical: 113 (63%), definite: 65 (37%); rheumatoid factor (RF) ≥1/64: 90 (51%), RF <1/64: 88 (49%).
†Including giant cell arteritis (eight), systemic sclerosis (four), primary Sjögren's syndrome (three), polymyositis (two), Raynaud's phenomenon alone (three), and mixed connective tissue disease (three).
‡Including arthrosis (98), compressive neuralgia (23), and algodystrophia (25).

chosen so that measurement accuracy was not limited by the scale inaccuracy. The reliability of the semiquantitative evaluation was ensured in each assay by a previous reading of three reference sera

of known intensity, acting as interassay controls. Moreover, three other known serum samples permitted the stability of the evaluation within each assay to be controlled.

Fig. 1 Histological patterns of labelling produced by IgG and IgM antibodies to rat oesophagus epithelium. (A) Histological structure of the cornified stratified squamous epithelium of rat oesophagus: stratum corneum (SC), stratum spinosum (SS), stratum basale (SB). (B) Rheumatoid arthritis specific IgG anti-stratum corneum antibodies (antikeratin antibodies): linear, laminated labelling restricted to the stratum corneum. (C) Non-disease-specific IgG antibodies: intense, diffuse, cytoplasmic labelling of the stratum spinosum and intense laminated labelling of the stratum corneum. (D) Non-disease-specific IgG antibodies: intense, diffuse, cytoplasmic labelling restricted to the stratum spinosum. (E) Non-disease-specific IgG antibodies: weak, diffuse labelling of the three epithelial compartments. (F) Non-disease-specific IgM antibodies: more or less laminated, heterogeneous labelling of the stratum corneum and weak flaky labelling of the stratum spinosum and the stratum basale. Bar=40 µm.

The morphological pattern of labelling in each epithelial compartment was analysed—for example, linear, laminated, diffuse, dusty, microgranular, or flaky in the stratum corneum, and cytoplasmic or pericellular, diffuse, microgranular, speckled, or flaky in the stratum spinosum and the stratum basale. The labelling of other histological structures of the oesophagus—for example, nuclei, basement membrane, smooth and striated muscle, was not recorded in this work.

OTHER SERUM ASSAYS

The total IgG was determined by radial immunodiffusion²² using IgG-HC NOR Partigen immunodiffusion plates purchased from Behring (Malburg, FRG). The IgM RF titre was obtained by a modification of the Waaler-Rose method²³; a titre of 1/64 was considered positive. Antinuclear antibodies were determined by indirect immunofluorescence on cryostat sections of mouse liver. Anti-single-stranded DNA (ssDNA) antibodies were assayed by Farr's method.²⁴ C reactive protein was determined by nephelometric assay with 'NA latex C reactive protein reagent' obtained from Behring (Malburg, FRG). Circulating immune complexes were detected by the procedure described by Zubler and Lambert.²⁵ Total complement was evaluated by its haemolytic activity and C3 and C4 complement fractions by nephelometric assay with specific antisera obtained from Behring (Malburg, FRG).

DATA ANALYSIS

Statistical analyses were performed with home made software on a BM60 computer (Bull-Micral, Massy, France). Each variable was analysed within each group of patients: distribution, mean, standard deviation, median, range. After variance comparison, mean differences were tested with Student's *t* test for the Gaussian variables and with Mann-Whitney's U test for the other variables. Similarly, correlations were sought using either Bravais-Pearson's or Spearman's rank correlation coefficient. A χ^2 test was used to compare percentages. The diagnostic value of antikeratin antibody detection was assessed by computing various diagnostic indices according to the following classical formula, in which true positives (TP) were patients with RA with a positive test, false positives (FP) were controls with a positive test, true negatives (TN) were controls with a negative test, and false negatives (FN) were patients with RA with a negative test. Sensitivity (TP/(TP+FN)) and specificity (TN/(TN+FP)) allowed the intrinsic value of antikeratin antibody detection in RA to be assessed. The positive predictive value—that is, the probability of

the diagnosis (TP/(TP+FP)), and the negative predictive value—that is, the probability of the diagnosis exclusion (TN/(TN+FN)), depending on RA prevalence, allowed the usefulness of the test to be determined in the actual clinical conditions of diagnostic use.

Results

All 528 serum samples were assayed for IgG and IgM antibodies to rat oesophagus. The antibodies of both classes were analysed histologically by morphological typing of the labelling in each compartment of the epithelium (stratum corneum, stratum spinosum, stratum basale) and semiquantitatively by grading of the fluorescence intensity separately in the three compartments. For both IgG and IgM antibodies, most serum samples belonging to all the diagnostic groups, labelled the three epithelial compartments, but with large interindividual variations in both morphological labelling pattern and fluorescence intensity (Fig. 1).

HISTOLOGICAL ANALYSIS OF IgG AND IgM ANTIBODIES TO RAT OESOPHAGUS EPITHELIUM

IgG antibodies

From the labelling of the stratum corneum and stratum spinosum produced by IgG antibodies, four typical patterns were distinguished (Table 2); two predominated. Intense, regular, linear, laminated labelling restricted to the stratum corneum was obtained almost exclusively with RA sera. Weak, diffuse, cytoplasmic labelling of the stratum basale and the stratum spinosum associated with weak and diffuse labelling of the stratum corneum was produced by numerous serum samples belonging to every diagnostic group (Fig. 1E). Besides these two predominant forms, we also found, but rarely, two other patterns: intense, linear, laminated labelling of the stratum corneum associated with equally intense, diffuse, cytoplasmic labelling of the stratum spinosum. This was produced by only four serum samples (Fig. 1C). Lastly, intense, diffuse, cytoplasmic labelling restricted to the stratum spinosum was given by only two sera (Fig. 1D). These two last patterns were independent of disease. In many cases pericellular labelling of the stratum basale, isolated or superimposed on these various patterns, was found. This morphological analysis placed a high proportion of serum samples (90.7%) in four histological classes. The other serum samples (9.3%) produced labelling patterns intermediate between these four types. The more frequently found showed laminated but weak labelling of the stratum corneum associated with

equally intense diffuse cytoplasmic labelling of the two other epithelial compartments. Because of the obvious high disease specificity of the exclusive labelling of the stratum corneum, and because of the existence of intermediate patterns including labelling of the stratum corneum, a semiquantitative estimation of its fluorescence intensity was carried out to determine the anti-stratum corneum antibody (or antikeratin antibody) titre-like value necessary for a diagnosis of RA.

IgM antibodies

In contrast with IgG antibodies, labelling of the various epithelial compartments by IgM antibodies did not distinguish a pattern for RA. The stratum corneum labelling was more or less laminated but always irregular and heterogeneous: dusty or microgranular, whatever the fluorescence intensity. The stratum spinosum and stratum basale were often stained, generally with a weak, microgranular, speckled, or flaky pattern (Fig. 1F). Although no pattern specific for RA was identified, semiquantitative analysis of the stratum corneum fluorescence intensity was performed to determine whether high titre IgM antikeratin antibodies were specific for RA or for any other disease.

SEMIQUANTITATIVE ANALYSIS OF IgG AND IgM ANTI-STRATUM CORNEUM ANTIBODIES OR ANTIKERATIN ANTIBODIES

IgG antikeratin antibodies

All along the fluorescence intensity scale, IgG

antikeratin antibodies were detected in 97.2% of sera from all the diagnostic groups (Fig. 2A). The mean value of IgG antikeratin antibodies was much higher in RA sera than in non-RA sera however (Mann-Whitney U test=6.23; $p < 10^{-8}$). Furthermore, the fluorescence intensity was restricted to low values with the controls (non-RA) whereas it extended all along the scale, from 0 to 7.75, with RA sera, showing that high titre IgG antikeratin antibodies are specific for RA (Fig. 2A). For each IgG antikeratin antibody semiquantitative value the diagnostic sensitivity and specificity were computed. The resulting curves showed that specificity increased rapidly up to a fluorescence intensity of 1.50 (Fig. 2B). At a fluorescence intensity of 1.50, 1.75, and 2.00 the specificity was 95.43%, 98%, and 99.14% and the sensitivity 56.18%, 47.75%, and 43.26%, respectively (Table 3). At fluorescence intensities higher than 3.25 although the sensitivity became weaker than 20% the specificity reached 100%. Thus high titre IgG antikeratin antibodies were found to be pathognomonic for RA. For all further statistical analyses we chose 2.00 as a threshold because it gave a specificity greater than 99% without serious loss of sensitivity. Above this threshold, the four sera giving a non-RA-specific pattern (Table 2) were excluded, and thus only three false positive sera remained (0.86% of non-RA sera): 1 systemic lupus erythematosus (2.00), 1 ankylosing spondylitis (2.25), and 1 Paget's disease (3.25). Moreover, IgG antikeratin antibodies were found to enhance the probability of RA diagnosis from 33.71% (prevalence of RA in our

Table 2 Distribution of RA* and non-RA sera in histological classes according to the intensity and morphological pattern of labelling of the stratum corneum and stratum spinosum of the rat oesophagus epithelium

Epithelial layer	Intensity	Pattern of labelling	Number (percentage) of sera		
			RA	Non-RA	Total
SC*	Intense	Linear			
SS*	Weak	Diffuse	65 (36.5)	3 (0.9)	69 (13.1)
SC	Weak	Diffuse			
SS	Weak	Diffuse	78 (43.8)	326 (93.1)	404 (76.5)
SC	Intense	Linear			
SS	Intense	Diffuse	0 (0)	4 (1.1)	4 (0.8)
SC	Null or weak	Diffuse			
SS	Intense	Diffuse	0 (0)	2 (0.6)	2 (0.4)
Miscellaneous intermediate patterns			35 (19.7)	15 (4.3)	49 (9.3)
Total (100%)			178	350	528

*RA=rheumatoid arthritis; SC=stratum corneum; SS=stratum spinosum.

Fig. 2 Fluorescence intensity distribution, diagnostic sensitivity and specificity of IgG anti-stratum corneum antibodies (antikeratin antibodies). (A) Distribution of rheumatoid arthritis (RA) and non-RA sera according to their IgG antikeratin antibody titre-like fluorescence value. The bars show the number of serum samples for each level on the semiquantitative scale of fluorescence intensity. Empty bars: from 0 to 1.25; hatched bars: from 1.50 to 1.75; filled bars: from 2.00 to 8.00. (B) Sensitivity (continuous line) and specificity (dashed line) were computed from the distribution above. Vertical lines show the thresholds of fluorescence intensity (1.50 and 2.00) which allowed specificities of more than 95% and more than 99% respectively, to be reached.

sample) to 96.25% (positive predictive value). In contrast, the probability of RA diagnosis exclusion was only slightly increased, from 66.29% (prevalence of non-RA sera) to 77.46% (negative predictive value).

IgM antikeratin antibodies

All along the fluorescence intensity scale, IgM antikeratin antibodies were detected in 83.9% of the sera from all the diagnostic groups. The mean value of IgM antikeratin antibodies was higher in RA sera

than in non-inflammatory control groups (Mann-Whitney U test=3.52; $p<0.001$) but did not differ from that of other inflammatory disease groups. The ranges of fluorescence intensity were from 0 to 7.25 for RA sera and from 0 to 6.25 for the non-RA sera. When a threshold giving a 99% diagnostic specificity for RA was chosen only 4.5% of RA sera (8/178) were detected. Thus IgM antikeratin antibodies are clearly non-disease specific.

RELATIONS BETWEEN IgG ANTIKERATIN ANTIBODIES AND OTHER CLINICAL AND BIOLOGICAL FEATURES OF RA

In patients with RA correlations were sought between IgG antikeratin antibodies and various other clinical and biological features (Table 4).

Sex ratio, age, and disease duration were not significantly different in the two IgG antikeratin antibody positive and IgG antikeratin antibody negative subgroups of patients. Although the percentages with classical RA (American Rheumatism Association criteria >7) were quite similar within the two IgG antikeratin antibody subgroups, subcutaneous nodules were twice as prevalent in IgG antikeratin antibody positive patients.

Among the serological variables, erythrocyte sedimentation rate and C reactive protein were significantly higher in IgG antikeratin antibody positive patients. Moreover, a significant correlation was found between the IgG antikeratin antibody titre and erythrocyte sedimentation rate ($r=0.203$, $p<0.05$) and between the IgG antikeratin antibody titre and the amount of C reactive protein ($r=0.305$, $p<0.001$). The mean RF titre was four times greater ($1/16$ v $1/64$) in IgG antikeratin antibody positive than in antibody negative patients. Similarly, the RF titre and IgG antikeratin antibody titre were significantly correlated ($r=0.336$, $p<0.001$). Nevertheless, 34% of RF negative patients (21/61) were IgG antikeratin antibody positive. The circulating immune complex titre was significantly higher in IgG antikeratin antibody positive patients and correlated well with the IgG antikeratin antibody titre ($r=0.333$, $p<0.001$). Finally, IgG antikeratin antibodies were independent of all the other studied immunological variables—that is, antinuclear antibodies and ssDNA antibodies, total amount of serum IgG, total serum complement, and C3 and C4 complement fractions.

Discussion

Since the report of Young *et al*⁸ antibodies associated with RA that react with rat oesophagus stratum corneum have always been called antikeratin antibodies,^{2 3 9-17} probably because of their labell-

Table 3 Diagnostic value of IgG anti-stratum corneum antibodies (IgG antikeratin antibodies). Diagnostic indices are expressed as percentages (5% confidence interval) for three consecutive fluorescence intensity thresholds

	Fluorescence intensity threshold		
	1-50	1-75	2-00
Sensitivity	56.18 (48.89 to 63.47)	47.75 (40.41 to 55.09)	43.26 (35.98 to 50.54)
Specificity	95.43 (93.24 to 97.62)	98.00 (96.53 to 99.47)	99.14 (98.18 to 100.0)
Positive predictive value	86.21 (79.93 to 92.48)	92.39 (86.97 to 97.81)	96.25 (92.09 to 100.0)
Negative predictive value	81.07 (77.29 to 84.85)	78.67 (74.82 to 82.51)	77.46 (73.59 to 81.32)

ing pattern and also because keratins are the major component of this epithelial compartment. The stratum corneum of the cornified stratified squamous epithelium of rat oesophagus, however, like the homologous compartment of human epidermis, contains, besides keratin polypeptides, a wide variety of other potentially antigenic molecules. On the other hand, we showed in a previous study, by a specific enzyme linked immunosorbent assay (ELISA), the existence of IgG and IgM naturally occurring autoantibodies directed to epidermal keratin polypeptides in all the normal human sera.²¹ In addition, we have investigated these autoantibodies in rheumatic diseases and have shown that they are of no diagnostic value for RA.

So, considering these various arguments and in the absence to date of any immunochemical evidence on the nature of the antigen recognised in rat oesophagus stratum corneum by the RA specific antibodies we think it would be more appropriate to call these antibodies anti-stratum corneum antibodies rather than antikeratin antibodies.

In this work we studied, in a large sample of patients with rheumatic diseases, the circulating IgG and IgM antibodies to rat oesophagus epithelium including antikeratin antibodies, by analysing the labelling pattern and evaluating their titre.

Histological analysis of IgG antibodies to the epithelium allowed us to describe four typical labelling patterns. Of the two found more frequently

Table 4 Relation between IgG anti-stratum corneum antibodies (IgG antikeratin antibodies) and various clinical data and serum variables in rheumatoid arthritis (RA). Values are given as mean (range) or number (%)

	IgG AKA * <2 (n=101)	IgG AKA ≥2 (n=77)	p Value
No (%) of men	18 (18)	14 (18)	NS
Age (years)	57.2 (19-81)	62.5 (35-82)	NS
Disease duration (years)	12.3 (0.5-32)	14.1 (1-43)	NS
No (%) with classic RA	62 (61)	51 (66)	NS
No (%) with subcutaneous nodules	18 (18)	27 (35)	0.020
ESR* (mm/1st h)	39.2 (2-130)	51.4 (2-130)	0.030
C reactive protein (mg/l)	40.2 (8-173)	66.5 (9-195)	0.001
IgM RF* (titre)	1/16 (1-1/1024)	1/64 (1-1/1024)	0.001
Antinuclear AB* (titre)	1/16 (1-1/2048)	1/16 (1-1/2048)	NS
Anti-single-stranded DNA AB (%)	5.9 (0-55)	2.3 (0-30)	NS
Circulating immune complexes (%)	5.5 (0-90)	9.7 (0-60)	0.001
IgG (g/l)	14.4 (5.5-31.5)	15.6 (6.0-21.9)	NS
Complement (% of normal)	109.4 (58-181)	110.0 (43-160)	NS
C3 (% of normal)	98.0 (58-158)	97.0 (49-151)	NS
C4 (% of normal)	115.0 (55-295)	110.0 (50-210)	NS

*AKA=antikeratin antibodies; ESR=erythrocyte sedimentation rate; RF=rheumatoid factor; AB=antibodies; C3, C4=serum complement fractions.

†The mean differences or percentage differences between the two subgroups were tested by the Mann-Whitney U test or χ^2 test respectively. The IgG antikeratin antibody positive subgroup of RA was defined by a stratum corneum fluorescence intensity ≥ 2.00 .

the intense linear laminated labelling restricted to the stratum corneum was highly specific for RA, while the weak diffuse labelling of the three epithelial compartments was found in some RA sera but also in numerous non-RA sera. Of the two other typical but scarce patterns, the exclusive labelling of the stratum spinosum was of no diagnostic value, while the equally intense labelling of stratum spinosum and stratum corneum permitted discrimination between the related antibodies and the RA specific antibodies and prevented the related sera from being considered as false positives. The patterns intermediate between these typical forms could result from the simultaneous presence of antibodies of different specificities—for example, low titre RA specific IgG antikeratin antibodies and other antiepithelial IgG in the same RA sera. In these cases only the semiquantitative evaluation of the stratum corneum fluorescence intensity permitted diagnosis. This quantitative approach also allowed us to show that IgG antikeratin antibody diagnostic sensitivity and specificity were closely linked to their titre (Fig. 2B). Indeed, up to a fluorescence intensity of 1.25 the specificity was considered insufficient (less than 95%), while from 2.25

the sensitivity became too weak for diagnostic use (less than 40%). To obtain the best compromise between sensitivity and specificity we chose 2.00 as a threshold because it allowed a diagnostic specificity of more than 99%. Thus for an individual serum a result below that threshold does not permit a diagnosis of RA to be excluded (low negative predictive value). At the threshold the diagnosis can be asserted with an error probability of 3.75% (high positive predictive value). Beyond the threshold the predictive value increases, and over a fluorescence intensity of 3.50 the test becomes pathognomonic for RA as the diagnosis can be asserted without computable error.

In contrast, IgM antibodies to this epithelium were present in almost all the serum samples with large interindividual variations in their labelling and in their titre. Moreover, no pattern specific for RA or for any other disease could be identified. Among them, IgM antikeratin antibodies, sometimes with a high titre, were found in RA as well as in non-RA sera and thus were clearly of no diagnostic value.

To summarise, the histological analysis of IgG antibodies to rat oesophagus epithelium permitted a histological pattern typical of RA specific IgG

Table 5 Diagnostic value in rheumatoid arthritis of anti-stratum corneum antibodies, so-called antikeratin antibodies, computed from studies reported since 1979. Only the studies performed on separate samples of patients were considered

Author	Ref	Class of AKA*	Number of sera	Number of positive sera/total				Sensitivity (%)	Specificity (%)
				RA*	Other rheumatic diseases	Miscellaneous non-rheumatic diseases	Normal controls		
Quismorio	11	Ig(?)	211	46/80	7/84		2/47	57.50	93.13
Hajiroussou	15	Ig(?)	304	121/204	6/100			59.31	94.00
1st group†		Ig(?)	515	167/284	13/184	0/0	2/47	58.80	93.51
Young	8	IgG	286	75/129	1/52		0/105	58.14	99.36
Johnson	2	IgG	219	52/102	2/47	1/10	0/60	50.98	97.44
Scott	9	IgG	165	36/99	8/16		0/50	36.36	87.88
Ordeig	12	IgG	566	71/131	7/266	2/69	0/100	54.20	97.93
Kataaha	13	IgG	205	39/72		0/40	0/93	54.17	100.00
Youniou	14	IgG	1072	156/421	5/91	13/313	6/247	37.05	96.31
Meyer	16	IgG	227	67/122	3/75		1/30	54.92	96.19
Kirstein	17	IgG	297	73/156	0/61		2/80	46.79	98.58
2nd group†		IgG	3037	569/1232	26/608	16/432	9/765	46.19	97.17
This study‡		IgG	528	(a)	100/178	16/350		56.18	95.43
				(b)	85/178	7/350		47.75	98.00
				(c)	77/178	3/350		43.26	99.14

*AKA=antikeratin antibodies; RA=rheumatoid arthritis.
†In the first two studies antikeratin antibodies were assayed using non-IgG specific antibodies, whereas in the second group of eight studies, as in this study, IgG specific antibodies were used. The tested sera were divided into four classes: RA, various other rheumatic diseases, miscellaneous non-rheumatic diseases, and normal control sera. Sensitivities and specificities were computed for each study and for each group of studies.
‡a, b, c: results computed according to three fluorescence intensity thresholds: (a) 1.50, (b) 1.75, and (c) 2.00.

antikeratin antibodies to be identified and thus allowed us to exclude some sera which would have been considered as false positive. The semiquantitative analysis permitted the high diagnostic relevance of IgG antikeratin antibody detection in RA to be confirmed and its diagnostic indices to be objectively established. Both analyses showed that IgM antikeratin antibody detection cannot constitute a diagnostic test.

Almost all the international reports on antikeratin antibodies (Table 5) since the first work of Young *et al.*, asserted their diagnostic relevance for RA.^{2,3,8,10-17} Only Scott *et al.* considered these antibodies to be 'of very limited value'.⁹ In all these studies the assayed serum samples were considered positive based on criteria which sometimes included the labelling pattern characteristics^{9,11,12,15,17} but which never referred to a definite fluorescence intensity level. Moreover, even the authors who performed a rough evaluation of the fluorescence intensity^{8,15} or an antibody titration by limit dilution^{3,11,14-16} did not consider the labelling produced by the so-called negative sera and always regarded it as background fluorescence. So, the diagnostic sensitivity and specificity were imposed on the investigators by their previously chosen detection threshold. This is probably the main explanation of the differences in sensitivity and specificity they reported, but the variations in the assay procedures they used or in the composition of

the patient samples they analysed, or both, can also explain these discrepancies. When antikeratin antibodies were investigated with non-IgG specific secondary antibodies able to detect all the immunoglobulin classes^{11,15} the percentage of positive RA sera reached 58.8%, while the false positives were found to exceed 6%. This can be explained by the simultaneous detection of IgM and IgG antikeratin antibodies, which can be present together in an RA serum, as shown by Quismorio *et al.*¹¹ and Ordeig *et al.*¹² and confirmed throughout our serum samples. Therefore, to define the true diagnostic value of IgG antikeratin antibody detection on a very large number of sera from various origins, the studies in which only the antikeratin antibodies belonging to the IgG class were considered as RA specific^{2,8,9,12-14,16,17} were analysed together with our results. In these studies the mean diagnostic sensitivity of IgG antikeratin antibodies was 46.1% ranging from 36.4% to 58.1%, which is roughly similar to the variation of sensitivity induced in this study by a slight threshold variation. On the other hand, if one excludes the results of Scott *et al.*,⁹ who found a high percentage of false positive sera (12%) the diagnostic specificity in the other studies was always better than 96%. Moreover, the mean percentage of false positives was found to vary slightly between the different control subgroups: 1.26% (9/715) of the normal sera, 3.70% (16/432) of the miscellaneous non-rheumatic sera, and only

Table 6 Relations between anti-stratum corneum antibodies, so-called antikeratin antibodies, and clinical data and serum variables in rheumatoid arthritis, reported since 1979. Only variables studied by at least two authors are included*

	References											This study
	2	9	3	10	11	12	13	14	15	16	17	
Sex (% men)						NS			++	NS	NS	NS
Age						+			NS	+	NS	NS
Disease duration			NS			NS			NS	NS	NS	NS
Functional indexes		NS		+		+			++	++		
Subcutaneous nodules		NS		+++		+		+	++	NS	NS	+
Sjögren's syndrome				+++		NS		NS	NS	NS		
Erythrocyte sedimentation rate		NS	+	+++						+++	NS	+
C reactive protein		NS		+++					+++			+++
IgM rheumatoid factor	+	+	+++	+++		++			+	+	+	+++
Antiperinuclear factor	+		+				NS					
Antinuclear antibodies		NS		+	NS	+			+	NS		NS
Soluble immune complexes	+++											+++
IgG		NS										NS
Complement										NS		NS

*For each variable a higher value in the antikeratin antibody positive subgroup or a correlation with antikeratin antibody titre, or both, was sought.

Significance of the tests is given as ++= $p<0.05$; +++= $p<0.01$; ++++= $p<0.001$; NS=non-significant; blank=not tested.

3.04% (18/592) of the rheumatic non-RA sera. In our study the percentage of false positives among the rheumatic non-RA sera ranged from 4.57% to 0.86% when the chosen threshold ranged from 1.50 to 2.00.

The relations between IgG antikeratin antibodies and other clinical and serological indexes of RA investigated in our series (Table 4) were analysed together with those reported in previous studies (Table 6). From the whole series of results we compared IgG antikeratin antibody detection with other diagnostic tests for RA and attempted to determine whether the antikeratin antibody positive patients belonged to a particular subgroup of RA, with regard to the other indexes of the disease.

The incidence and titre of IgG antikeratin antibodies were found to be significantly correlated with IgM RF by all the authors who investigated such a correlation,^{2 3 9 10 12 15-17} and in both respects we agree with these results. As in previous studies,^{3 12 16 17} however, we showed that a large percentage of RF negative RA (34.43%) can be diagnosed by IgG antikeratin antibody detection. Antiperinuclear factor was also found to be correlated with IgG antikeratin antibodies by Johnson *et al* and by Miossec *et al*.^{2 3} RF, and to a lesser degree antiperinuclear factor, have some diagnostic use in RA,¹⁻³ but the high number of false positive sera, especially among the other connective tissue diseases,⁸ reduces the diagnostic relevance of these two factors. IgG antikeratin antibody detection, though less sensitive, is highly RA specific and thus is most important in diagnosis of the disease. Thus detection of IgG antikeratin antibodies is the most useful of these three tests for the diagnosis of RA. Indeed, if IgG antikeratin antibodies are present, especially at a high titre, the diagnosis of RA is clearly established.

On the other hand, we found no correlation between IgG antikeratin antibodies and antibodies to nuclear antigens, whereas in previous studies^{9-12 15 16} such a correlation was shown, but only by three authors.^{10 12 15} The other auto-antibodies investigated (to cartilage, smooth muscle, thyroid, gastric parietal cells, mitochondria, reticulin, vimentin) were never found to be related to IgG antikeratin antibodies.^{9 11 15} Lastly, we confirmed⁹ that IgG antikeratin antibodies vary independently of total serum IgG concentration. In this study, as found previously, various biological and clinical indexes related to disease severity or activity, or both, were found to be associated with IgG antikeratin antibodies. We confirmed that IgG antikeratin antibodies are associated with increased erythrocyte sedimentation rate^{3 10 16} and especially

with increased concentrations of C reactive protein,^{10 15} and we showed in agreement with Johnson *et al*,² a correlation between IgG antikeratin antibodies and circulating immune complexes. Among the extra-articular features of the disease, we found a higher incidence of subcutaneous nodules in the IgG antikeratin antibody positive patients, as reported by most other authors.^{10 12 14 15} An association with Sjögren's syndrome was also found but only by Mallya *et al*.¹⁰ Finally, a significant association between IgG antikeratin antibodies and various functional criteria such as Steinbrocker's index²⁸ was also shown.^{10 12 15 16} All these correlations suggest that IgG antikeratin antibodies are probably associated with the most severe or active forms of RA. Nevertheless, in agreement with Meyer *et al*,¹⁶ the total haemolytic complement activity, like the C3 and C4 fractions, was found to be normal in both the IgG antikeratin antibody positive and negative RA subgroups.

Disease duration was never found to be related with the incidence of IgG antikeratin antibodies,^{3 12 15-17} and this was confirmed in our series by both incidence and titre. This independence may indicate, as suggested by Ordeig *et al*,¹² that IgG antikeratin antibodies appear at the beginning, indeed may even precede the disease, and thus may be useful for the early diagnosis of RA. Nevertheless, only further longitudinal studies will be able to define the value of IgG antikeratin antibodies in predicting the development of RA.

We think that indirect immunofluorescence detection of antikeratin antibodies should be used more widely. To ensure interlaboratory reproducibility, however, the following procedure should be used. The middle third of rat oesophagus must be used as substrate as it allows the best diagnostic sensitivity and specificity to be obtained.^{9 11} IgG antikeratin antibodies must be detected with secondary antibodies specific for human IgG to prevent the simultaneous detection of non-RA-specific IgM antikeratin antibodies. The histological labelling pattern must be analysed to identify false positive sera (Fig. 2C). Evaluation of the titre, either semiquantitatively by fluorescence intensity or by a dilution titration method, is also necessary because the specificity depends on the titre, and also the classification as positive or negative of sera which do not present a typical histological pattern of labelling would become possible. Each laboratory will easily be able to establish its own reference standards with two samples of well characterised sera from patients with or without RA. A specific immunoassay is awaited, but meanwhile the various groups trained in this aspect of immunorheumatology could colla-

borate to select reference sera, thus leading to international standardisation.

In conclusion, the diagnostic value of antikeratin antibodies has been assessed by 11 research groups working with 4080 patients, including 1694 with RA, coming from 10 places in five countries—that is, from genetically heterogeneous populations. Analysis of all the results obtained by us and other workers under comparable technical conditions^{2 8 12-14 16 17} shows that the mean diagnostic sensitivity of IgG antikeratin antibody detection is better than 46% and the mean specificity is near 98%. This test must, therefore, be considered as the most specific biological criterion for the diagnosis of RA, which actually becomes pathognomonic when IgG antikeratin antibodies are present in a high titre. IgG antikeratin antibodies are more specific for RA than are RFs, and, moreover, allow a high percentage of RF negative RA to be diagnosed. Furthermore, IgG antikeratin antibodies may have some prognostic significance as the subgroup of RA defined by high IgG antikeratin antibody titres seems to correspond to more severe or more active forms of the disease. It remains to be determined whether IgG antikeratin antibodies are present at a weak titre in all human sera and only increased in RA or whether they result from a synthesis specific for patients with RA. In the same way their possible pathogenic significance remains, to date, totally unexplored.

We thank M F Isaia, M P Rué, and J P Basile for their valuable technical assistance. We also thank Dr M Stebenet, Laboratoire de Biochimie II, Dr F Oksman and Dr Smilovici, Centre Régional de Transfusion Sanguine, Hôpital Purpan, Toulouse, for providing some of the biological data. Supported in part by grants from the Association pour la Recherche contre le Cancer, the Ligue contre le Cancer, and the Conseil Régional de Midi-Pyrénées.

References

- Nienhuis R L F, Mandema E, Smids C. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. *Ann Rheum Dis* 1964; **23**: 302-5.
- Johnson G D, Carvalho A, Holborow E J, Goddard D H, Russell G. Antiperinuclear factor and keratin antibodies in rheumatoid arthritis. *Ann Rheum Dis* 1981; **40**: 263-6.
- Miossec P, Youinou P, Le Goff P, Moineau M P. Clinical relevance of antikeratin antibodies in rheumatoid arthritis. *Clin Rheumatol* 1982; **1**: 185-9.
- Menzel J, Steffen C, Kolarz G, Eberl R, Frank O, Thumb N. Demonstration of antibodies to collagen and of collagen-anticollagen immune complexes in rheumatoid arthritis synovial fluid. *Ann Rheum Dis* 1976; **35**: 446-50.
- Andersen I, Andersen P, Graudal H. Smooth-muscle antibodies in rheumatoid arthritis. *Acta Pathologica et Microbiologica Scandinavica. Section C, Immunology* 1980; **88**: 131-5.
- Osung O A, Chandra M, Holborow E J. Antibodies to intermediate filaments of the cytoskeleton in rheumatoid arthritis. *Ann Rheum Dis* 1982; **41**: 69-73.
- Senecal J L, Olivier J M, Rothfield N. Anticytoskeletal autoantibodies in the connective tissue diseases. *Arthritis Rheum* 1985; **28**: 889-95.
- Young B J J, Mallya R K, Leslie R D J, Clark C J M, Hamblin T J. Anti-keratin antibodies in rheumatoid arthritis. *Br Med J* 1979; **ii**: 97-9.
- Scott D L, Delamere J P, Jones L J, Walton K W. Significance of laminar antikeratin antibodies to rat oesophagus in rheumatoid arthritis. *Ann Rheum Dis* 1981; **40**: 267-71.
- Mallya R K, Young B J J, Pepys M B, Hamblin T J, MacBride W, Hamilton E B D. Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. *Clin Exp Immunol* 1983; **51**: 17-20.
- Quismorio F P, Kaufman R L, Beardmore T, Mongan E. Reactivity of serum antibodies to the keratin layer of rat oesophagus in patients with rheumatoid arthritis. *Arthritis Rheum* 1983; **26**: 494-9.
- Ordeig J, Guardia J. Diagnostic value of antikeratin antibodies in rheumatoid arthritis. *J Rheumatol* 1984; **11**: 602-4.
- Kataaah P K, Mortazavi-Milani S M, Russel G, Holborow E. Anti-intermediate filament antibodies, antikeratin antibodies and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis. *Ann Rheum Dis* 1985; **44**: 446-9.
- Youinou P, Le Goff P, Colaco C B, et al. Antikeratin antibodies in serum and synovial fluid show specificity for rheumatoid arthritis in a study of connective tissue diseases. *Ann Rheum Dis* 1985; **44**: 450-4.
- Hajrioussou V J, Skingle J, Gillett A P, Webley M. Significance of antikeratin antibodies in rheumatoid arthritis. *J Rheumatol* 1985; **12**: 57-9.
- Meyer O, Fabregas D, Cyna L, Ryckewaert A. Les anticorps anti-kératine. Un marqueur des polyarthrites rhumatoïdes évolutives. *Rev Rhum Mal Osteoartic* 1986; **53**: 601-5.
- Kirstein H, Mathiesen F K. Antikeratin antibodies in rheumatoid arthritis. *Scand J Rheumatol* 1987; **16**: 331-7.
- Ropes M W, Bennett G A, Cobb S, Jacox R, Jessar R A. A revision of the diagnostic criteria for rheumatoid arthritis. *Ann Rheum Dis* 1958; **9**: 175-6.
- Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; **31**: 315-24.
- Serre G, Vincent C, Mauduyt M A, Soleilhavoup J P, Planel H. Morphologic, quantitative and cytoenzymologic studies of synoviocytic and monocytic cells in synovial fluid. *Analytical and Quantitative Cytology* 1984; **6**: 227-37.
- Serre G, Vincent C, Viraben R, Soleilhavoup J-P. Natural IgG and IgM autoantibodies to epidermal keratins in normal human sera. I. ELISA titration, immunofluorescence study. *J Invest Dermatol* 1987; **88**: 21-7.
- Mancini G, Carbonara A O, Heremans J F. Immunochemical quantitations of antigens by single radial immunodiffusion. *Immunochemistry* 1965; **2**: 235-45.
- Podliachouk L, Eyquem A, Jacqueline F. Le diagnostic de la polyarthrite chronique évolutive par agglutination de globules rouges humains sensibilisés. *Ann Inst Pasteur Immunol* 1958; **94**: 659-62.
- Farr R S. A quantitative immunochemical measure of the primary interaction between I BSA and antibody. *J Infect Dis* 1958; **103**: 239.
- Zubler R H, Lambert P H. ¹²⁵I C1q binding test for soluble immune complexes. *Ann Rheum Dis* 1977; **36**: 627-30.
- Serre G, Vincent C, Viraben R, Soleilhavoup J P. Autoantibodies to keratins in normal human sera, systemic lupus erythematosus, rheumatoid arthritis and psoriasis. *Eur J Clin Invest* 1985; **115**: A36.
- Serre G, Vincent C, Lapeyre F, Fournié B, Soleilhavoup J, Fournié A. Anticorps anti-stratum corneum d'oesophage de rat, autoanticorps anti-kératines et anti-épiderme dans la polyarthrite rhumatoïde et diverses affections rhumatologiques. Intérêt diagnostique, aspects fondamentaux. *Rev Rhum Mal Osteoartic* 1986; **53**: 607-14.
- Steinbrocker O, Traeger C H, Batterman R C. Therapeutic criteria in rheumatoid arthritis. *JAMA* 1949; **140**: 659-62.